KRMD Repro Med Systems Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KRMD

Price (delayed)

$4.13

Market cap

$189.7M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.05

Enterprise value

$184.3M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 41

Repro Med Systems, Inc. dba KORU Medical System develops, manufactures, and commercializes innovative and easy-to-use specialty infusion solutions that improve quality of life for patients around the world. The FREEDOM ...

Highlights
The net income has surged by 57% year-on-year and by 14% since the previous quarter
KRMD's EPS has surged by 55% year-on-year and by 17% since the previous quarter
The quick ratio has contracted by 11% YoY and by 10% from the previous quarter
The gross margin has contracted by 2.5% YoY
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: http://www.repro-med.com
Peers: OFIX

Key stats

What are the main financial stats of KRMD

KRMD stock price

How has the Repro Med Systems stock price performed over time
Intraday
5.36%
1 week
-1.2%
1 month
3.51%
1 year
46.45%
YTD
-28.92%
QTD
-4.4%

Financial performance

How have Repro Med Systems's revenue and profit performed over time
Revenue
$43.26M
Gross profit
$26.79M
Operating income
-$2.59M
Net income
-$2.28M
Gross margin
61.9%
Net margin
-5.3%
KRMD's net margin has surged by 65% year-on-year and by 17% since the previous quarter
The company's operating margin has surged by 63% YoY and by 17% QoQ
The net income has surged by 57% year-on-year and by 14% since the previous quarter
KRMD's operating income has soared by 55% YoY and by 13% from the previous quarter

Price vs fundamentals

How does KRMD's price correlate with its fundamentals

Growth

What is Repro Med Systems's growth rate over time

Valuation

What is Repro Med Systems stock price valuation
P/E
N/A
P/B
11.32
P/S
4.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.26
KRMD's EPS has surged by 55% year-on-year and by 17% since the previous quarter
KRMD's price to book (P/B) is 58% higher than its 5-year quarterly average of 6.8 but 11% lower than its last 4 quarters average of 12.1
The company's equity rose by 3.5% YoY
The revenue has grown by 23% YoY and by 5% from the previous quarter
The P/S is 18% below the 5-year quarterly average of 5.1 and 16% below the last 4 quarters average of 5.0

Efficiency

How efficient is Repro Med Systems business performance
KRMD's return on sales has surged by 66% year-on-year and by 19% since the previous quarter
Repro Med Systems's return on assets has surged by 57% YoY and by 15% QoQ
KRMD's return on invested capital has surged by 55% year-on-year and by 13% since the previous quarter
Repro Med Systems's ROE has soared by 55% YoY and by 14% from the previous quarter

Dividends

What is KRMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KRMD.

Financial health

How did Repro Med Systems financials performed over time
The total assets is 145% more than the total liabilities
The quick ratio has contracted by 11% YoY and by 10% from the previous quarter
The company's total liabilities rose by 7% YoY and by 4.6% QoQ
KRMD's debt is 80% smaller than its equity
The debt to equity fell by 13% YoY and by 4.8% QoQ
KRMD's debt is down by 10% year-on-year and by 3.7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.